Laurie Stelzer

Laurie Stelzer is recorded as CFO at Pfizer Inc (PFE), Board Member at MBX Biosciences, Inc. (MBX) and Board Member at Spyre Therapeutics, Inc. (SYRE). The newest filing on record that lists Laurie Stelzer as Board Member at MBX Biosciences, Inc. (MBX) is dated April 22, 2026. The newest filing on record that lists Laurie Stelzer as Board Member at Spyre Therapeutics, Inc. (SYRE) is dated April 10, 2026. Laurie Stelzer was last confirmed as Board Member at PMV Pharmaceuticals, Inc. (PMVP) in a filing dated April 25, 2025. Spyre Therapeutics, Inc. reported in an 8-K filed May 29, 2026 that Laurie Stelzer was appointed Class I director, effective May 27, 2026. MBX Biosciences, Inc. reported in an 8-K filed January 22, 2026 that Laurie Stelzer was appointed chairperson of the Audit Committee of the Board, effective January 20, 2026. MBX Biosciences, Inc. reported in an 8-K filed January 22, 2026 that Laurie Stelzer was appointed director, effective January 20, 2026. Equibles holds 5 filed executive changes naming Laurie Stelzer; each is listed under recent activity with its source filing. MBX Biosciences, Inc. is classified in the Biotechnology industry within the Healthcare sector. Pfizer Inc is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at MBX Biosciences, Inc. includes Steven Hoerter (CEO and Chairman), John Smither (CFO), Ed Mathers (Board Member) and 7 others.